CSIMarket
 


Oxford Immunotec Global Plc  (OXFD)
Other Ticker:  
 
 

OXFD's Net Income Growth by Quarter and Year

Oxford Immunotec Global Plc's Net Income results by quarter and year




OXFD Net Income (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter December - -1.62 141.06 4.72
III Quarter September -0.15 0.72 -3.48 -16.85
II Quarter June -9.69 0.59 -6.47 -16.77
I Quarter March -6.03 -1.50 -10.33 -4.86
FY   -15.87 -1.81 120.78 -33.76



OXFD Net Income third quarter 2020 Y/Y Growth Comment
Oxford Immunotec Global Plc in the third quarter 2020 recorded net loss of $ -0.15 millions.

According to the results reported in the third quarter 2020, Oxford Immunotec Global Plc achieved the best Net Income growth in In Vitro & In Vivo Diagnostic Substances industry. While Oxford Immunotec Global Plc' s Net Income no change of % ranks overall at the positon no. 826 in the third quarter 2020.




OXFD Net Income ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter December - - 2888.56 % -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Oxford Immunotec Global Plc's third quarter 2020 Net Income $ -0.15 millions OXFD's Income Statement
Oxford Immunotec Global Plc's third quarter 2019 Net Income $ 0.72 millions Quarterly OXFD's Income Statement
New: More OXFD's historic Net Income Growth >>


OXFD Net Income (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter December - - - -
III Quarter September - 22.03 % - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income third quarter 2020 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #0
Healthcare Sector #76
Overall #826

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income third quarter 2020 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #0
Healthcare Sector #76
Overall #826
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Oxford Immunotec Global Plc's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


OXFD's III. Quarter Q/Q Net Income Comment
Despite the fact, that Oxford Immunotec Global Plc in the III. Quarter 2020 revealed net loss of $ -0.15 millions, it should be said, that current results point to recovery compare to the -9.69 millions in the second quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Oxford Immunotec Global Plc achieved highest sequential Net Income growth. While Oxford Immunotec Global Plc's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


OXFD's III. Quarter Q/Q Net Income Comment
Although Oxford Immunotec Global Plc in the III. Quarter 2020 admitted net loss of $ -0.15 millions, it should be point out, that this show slight up side in contrast to the -9.69 millions in the second quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Oxford Immunotec Global Plc achieved highest sequential Net Income growth. While Oxford Immunotec Global Plc's Net Income growth quarter on quarter, overall rank is .


Oxford Immunotec Global Plc's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
12 Months Ending
(Dec 31 2019)
12 Months Ending
(Sep 30 2019)
Cumulative Net Income 12 Months Ending $ -17.48 $ -16.62 $ -6.34 $ -1.81 $ 140.87
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - 3.07 %
Seq. Net Income Growth (TTM) Overall Ranking # 826 # 0 # 0 # 0 # 749




Cumulative Net Income growth Comment
Oxford Immunotec Global Plc realized trailing twelve months net loss of $ -17 millions, in the Sep 30 2020, compare to Net Income of $ 141 millions a year ago.

Oxford Immunotec Global Plc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 0
Sector # 76
S&P 500 # 826
Cumulative Net Income growth Comment
Oxford Immunotec Global Plc realized trailing twelve months net loss of $ -17 millions, in the Sep 30 2020, compare to Net Income of $ 141 millions a year ago.

Oxford Immunotec Global Plc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 0
Sector # 76
S&P 500 # 826




Other Net Income Growth
In Vitro & In Vivo Diagnostic Substances Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
OXFD's Net Income Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for OXFD's Competitors
Net Income Growth for Oxford Immunotec Global Plc's Suppliers
Net Income Growth for OXFD's Customers

You may also want to know
OXFD's Annual Growth Rates OXFD's Profitability Ratios OXFD's Asset Turnover Ratio OXFD's Dividend Growth
OXFD's Roe OXFD's Valuation Ratios OXFD's Financial Strength Ratios OXFD's Dividend Payout Ratio
OXFD's Roa OXFD's Inventory Turnover Ratio OXFD's Growth Rates OXFD's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Sep 30 2020 within Healthcare SectorY/Y Change %Net Income for the quarter ending Sep 30 2020
Tenax Therapeutics Inc -0.15%$ -0.147 millions
Tactile Systems Technology Inc -0.29%$ -0.288 millions
Conmed Corporation-1.72%$ -1.722 millions
Mylan N v -2.16%$ -2.160 millions
Eli Lilly And Company-3.63%$ -3.629 millions
Baxter International Inc -4.27%$ -4.267 millions
Viemed Healthcare Inc -5.27%$ -5.270 millions
Icu Medical Inc-5.94%$ -5.937 millions
Emergent Biosolutions Inc -8.56%$ -8.565 millions
Bruker Corporation-10.08%$ -10.081 millions
3m Company-10.77%$ -10.768 millions
Innoviva Inc -11.54%$ -11.541 millions
Acadia Healthcare Company Inc -12.08%$ -12.082 millions
Biospecifics Technologies Corp-14.13%$ -14.129 millions
China Health Industries Holdings Inc -15.45%$ -15.449 millions
Encompass Health Corporation-16.23%$ -16.234 millions
Corcept Therapeutics Inc-17.90%$ -17.901 millions
Heartbeam Inc -18.94%$ -18.942 millions
Intuitive Surgical Inc -20.54%$ -20.542 millions
Utah Medical Products Inc-20.84%$ -20.837 millions
89bio Inc -22.01%$ -22.013 millions
Becton Dickinson And Company-22.09%$ -22.086 millions
Illumina Inc -23.50%$ -23.504 millions
Atrion Corporation-24.51%$ -24.513 millions
American Renal Associates Holdings Inc -24.90%$ -24.902 millions
Carlisle Companies Incorporated-25.82%$ -25.816 millions
Fonar Corporation-27.85%$ -27.852 millions
National Healthcare Corp-33.59%$ -33.588 millions
Msa Safety Incorporated-33.74%$ -33.740 millions
Zynex inc -34.43%$ -34.432 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com